Owing to its target potency and favorable pharmacokinetic properties, MTI-31 inhibited mTOR signaling function in vivo and demonstrated single agent oral antitumor efficacy in tumor models of HER2+/PIK3CAmut breast cancer, PTEN/VHL-null renal cancer and others. Here, ERBB2 is linked to neoplasm.